Heather White
Director Técnico/Científico/I+D en ALBIREO PHARMA, INC. .
Cargos activos de Heather White
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ALBIREO PHARMA, INC. | Director Técnico/Científico/I+D | 02/03/2023 | - |
Historial de carrera de Heather White
Antiguos cargos conocidos de Heather White.
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| AMICUS THERAPEUTICS, INC. | Director/Miembro de la Junta | 01/01/2008 | - |
Schering-Plough Ltd.
 Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Director Técnico/Científico/I+D | 01/01/1997 | - |
| IPSEN | Comptroller/Controller/Auditor | 01/01/2014 | - |
Formación de Heather White.
| The University of Liverpool | Graduate Degree |
Estadísticas
Internacional
| Reino Unido | 3 |
| Estados Unidos | 3 |
| Francia | 2 |
Operativa
| Chief Tech/Sci/R&D Officer | 2 |
| Comptroller/Controller/Auditor | 1 |
| Director/Board Member | 1 |
Sectorial
| Health Technology | 5 |
| Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| IPSEN | Health Technology |
| AMICUS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 2 |
|---|---|
Schering-Plough Ltd.
Schering-Plough Ltd. Pharmaceuticals: MajorHealth Technology Schering-Plough Ltd. manufactures and distributes pharmaceutical products. Its products include medicines for vascular diseases, oncology, opioid tendency, sexual health and virology. The company was founded on December 31, 1884 and is headquartered in Walton, the United Kingdom. | Health Technology |
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Bolsa de valores
- Insiders
- Heather White
- Experiencia
